🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 billion deal

Published 11/13/2024, 12:42 PM
Updated 11/13/2024, 12:51 PM
© Reuters. FILE PHOTO: A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. REUTERS/Tom Little/File Photo
LLY
-
NVO
-
CTLT
-

By Foo Yun Chee and Maggie Fick

BRUSSELS/LONDON (Reuters) - EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent (NYSE:CTLT), people familiar with the matter said.

Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk (NYSE:NVO), whose profits from blockbuster weight-loss drug Wegovy propelled it to become Europe's most valuable company by market value.

While the questionnaire shows the European Commission seeking to understand the market, it could allow rivals and customers to flag potential anti-competitive concerns. 

The questionnaire seeks feedback on vertical links in parts of the contract development and manufacturing organisation (CDMO) industry, including injectables, pre-filled syringes orally dissolved pills, and soft gels, the sources said.

The regulator distributed it to big pharma and CDMO companies, the sources said. This came after Novo Holdings put in a request for EU approval for the deal on Oct. 31.

The EU watchdog has set a Dec. 6 deadline for its preliminary review. Novo Holdings has until Nov. 29 to offer remedies during this phase, if any are required. 

European Union regulators can either clear the deal with or without remedies, or open a full-scale, four-month investigation if they have serious concerns.

The $16.5 billion deal, announced in February, underscores Novo Nordisk's drive to boost output of Wegovy, a once-weekly injection.

After the deal closes, Novo Holdings will sell three of Catalent's fill-finish sites - in Italy, Belgium and the United States - onto Novo Nordisk for $11 billion. The sites will then by fully used by Novo Nordisk for filling its injection pens.

Novo Holdings, Novo Nordisk and Catalent all recently reiterated their expectations that the transaction will close towards the end of this year.

In May, the companies said they had received a second request from the U.S. Federal Trade Commission (FTC) for more information on the deal. There has been no update from the FTC on its review of the deal since then.

Novo Nordisk faces competition from U.S. rival Eli Lilly (NYSE:LLY)'s injection Zepbound in the fast-growing obesity drug race. Some analysts have estimated the market could be worth as much as $150 billion by the early 2030s.

© Reuters. FILE PHOTO: A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. REUTERS/Tom Little/File Photo

U.S-based Catalent, one of the world's largest contract manufacturers, made a huge windfall during the COVID-19 pandemic as it was contracted to help make vaccines by several companies.

But the company faced a range of problems in the pandemic's aftermath, as COVID-vaccine revenue fell and its costs increased due to actions to address quality control lapses identified during inspections by U.S. drug regulators at three plants.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.